Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Pharmaceutical
Belgium’s largest drugmaker UCB today released financial results for the first half of 2024, which beat analysts’ expectations. 25 July 2024
Pharmaceutical
AstraZeneca (LSE: AZN) announced robust financial results for the second quarter of 2024, with a 13% increase in total revenue to $12.94 billion, driven by a strong performance across its key therapeutic areas. 25 July 2024
Biotechnology
US pharma giant Merck & Co has released positive top-line results from its Phase IIb/III clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), 24 July 2024
Biotechnology
Former executives at Johnson & Johnson (NYSE: JNJ) have teamed up to launch a new biotech company, Third Arc Bio, with significant backing from investors. 24 July 2024
Biotechnology
Tuesday was not a good day for shareholders in US biopharma Cellectar Biosciences—a US biopharma focused on the discovery, development and commercialization of drugs for the treatment of cancer. 23 July 2024
Pharmaceutical
In San Francisco, RAPT Therapeutics (Nasdaq: RAPT) has announced a substantial workforce reduction as part of its cash conservation strategy. 23 July 2024
Pharmaceutical
Innovent Biologics (HKEX: 01801) has announced positive results from the Phase III DREAMS-1 trial of mazdutide. 23 July 2024
Biotechnology
California-based liver and viral disease specialist Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Amoytop Biotech. 23 July 2024
Pharmaceutical
Spanish dermatology specialist Almirall was trading 4% higher at the end of Monday’s trading day in Barcelona. 22 July 2024
Biosimilars
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) submitted by South Korea’s Samsung Bioepis for Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab). 22 July 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze